These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 30987257)

  • 61. Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer.
    Saxena P; Singh PK; Malik PS; Singh N
    Curr Treat Options Oncol; 2020 Jul; 21(8):69. PubMed ID: 32720019
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Inhibitors of the PD-1/PD-L1 axis for the treatment of head and neck cancer: current status and future perspectives.
    Ran X; Yang K
    Drug Des Devel Ther; 2017; 11():2007-2014. PubMed ID: 28721019
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Exceptional response to cetuximab monotherapy after failure of immunotherapy with a checkpoint inhibitor in a patient with metastatic head and neck squamous cell cancer: case report and review of the literature.
    Bloomer CH; Gavrila E; Burcher KM; Kalada JM; Chang MJ; Gebeyehu RR; Asare E; Khoury LM; Kinney R; Frizzell B; Sullivan CA; Bunch PM; Porosnicu M
    Ther Adv Med Oncol; 2023; 15():17588359231193722. PubMed ID: 37667781
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Combination therapy with immune checkpoint inhibitors in recurrent or metastatic squamous cell carcinoma of the head and neck: A meta-analysis.
    Chen L; Mo DC; Hu M; He W; Yang QW; Tang J
    Int Immunopharmacol; 2023 Jun; 119():110270. PubMed ID: 37150013
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Immune Checkpoint Inhibition in Head and Neck Cancer.
    Forster MD; Devlin MJ
    Front Oncol; 2018; 8():310. PubMed ID: 30211111
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Immunotherapeutic studies of head and neck tumors : Highlights of the 2016 ASCO Annual Meeting].
    Busch CJ; Laban S; Knecht R; Hoffmann TK
    HNO; 2016 Oct; 64(10):708-16. PubMed ID: 27604282
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Real-world use of first-line pembrolizumab + platinum + taxane combination regimens in recurrent / metastatic head and neck squamous cell carcinoma.
    Black CM; Zheng D; Hair GM; Ai L; Wang L; Goto D; Lerman N; Bidadi B; Hanna GJ
    Front Oncol; 2024; 14():1348045. PubMed ID: 38390265
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Window-of-opportunity clinical trials for biomarker discovery in head and neck squamous cell carcinoma.
    Marret G; Borcoman E; Le Tourneau C
    Curr Opin Oncol; 2023 May; 35(3):158-165. PubMed ID: 36966501
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Microenvironment-driven intratumoral heterogeneity in head and neck cancers: clinical challenges and opportunities for precision medicine.
    Van den Bossche V; Zaryouh H; Vara-Messler M; Vignau J; Machiels JP; Wouters A; Schmitz S; Corbet C
    Drug Resist Updat; 2022 Jan; 60():100806. PubMed ID: 35121337
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Cervical cancer - State of the science: From angiogenesis blockade to checkpoint inhibition.
    Minion LE; Tewari KS
    Gynecol Oncol; 2018 Mar; 148(3):609-621. PubMed ID: 29666026
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Weekly paclitaxel, carboplatin and cetuximab (PCE) combination followed by nivolumab for recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
    Takeshita N; Enokida T; Okano S; Fujisawa T; Wada A; Sato M; Tanaka H; Tanaka N; Onaga R; Hoshi Y; Sakashita S; Ishii G; Tahara M
    Oral Oncol; 2023 Dec; 147():106615. PubMed ID: 37931493
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
    Caponigro F; Di Gennaro E; Ionna F; Longo F; Aversa C; Pavone E; Maglione MG; Di Marzo M; Muto P; Cavalcanti E; Petrillo A; Sandomenico F; Maiolino P; D'Aniello R; Botti G; De Cecio R; Losito NS; Scala S; Trotta A; Zotti AI; Bruzzese F; Daponte A; Calogero E; Montano M; Pontone M; De Feo G; Perri F; Budillon A
    BMC Cancer; 2016 Nov; 16(1):918. PubMed ID: 27884140
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Immunological Agents Used in Cancer Treatment.
    Simsek M; Tekin SB; Bilici M
    Eurasian J Med; 2019 Feb; 51(1):90-94. PubMed ID: 30911265
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment-A Review From the Melanoma Perspective and Beyond.
    Buder-Bakhaya K; Hassel JC
    Front Immunol; 2018; 9():1474. PubMed ID: 30002656
    [TBL] [Abstract][Full Text] [Related]  

  • 76. PD-1/PD-L1 inhibitor plus chemotherapy versus standard of care in the first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma.
    Mo DC; Huang JF; Luo PH; Chen L; Zou B; Wang HL
    Eur Arch Otorhinolaryngol; 2023 Jan; 280(1):1-9. PubMed ID: 35907001
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
    Vokes EE; Chu E
    Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck.
    Le Tourneau C; Siu LL
    Curr Opin Oncol; 2008 May; 20(3):256-63. PubMed ID: 18391623
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The Use of Immune Regulation in Treating Head and Neck Squamous Cell Carcinoma (HNSCC).
    Wang CW; Biswas PK; Islam A; Chen MK; Chueh PJ
    Cells; 2024 Feb; 13(5):. PubMed ID: 38474377
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Early investigational drugs that target epidermal growth factor receptors for the treatment of head and neck cancer.
    Ugurluer G; Ozsahin M
    Expert Opin Investig Drugs; 2014 Dec; 23(12):1637-54. PubMed ID: 25134724
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.